The reason is that these drugs may have the potential to eliminate tumor cells exhibiting HER2 dimerization and already activating downstream carcinogenic pathways, whereas conventional IHC methods may not currently detect HER2 dimerization states. This evidence concerns the gene ERBB2 and neoplasm.